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OBJECTIVE—Compelling epidemiological and clinical evi-
dence has identiﬁed a speciﬁc cardiomyopathy in diabetes,
characterized by early diastolic dysfunction and adverse struc-
tural remodeling. Activation of the insulin-like growth factor 1
(IGF-1) receptor (IGF-1R) promotes physiological cardiac
growth and enhances contractile function. The aim of the present
study was to examine whether cardiac-speciﬁc overexpression of
IGF-1R prevents diabetes-induced myocardial remodeling and
dysfunction associated with a murine model of diabetes.
RESEARCH DESIGN AND METHODS—Type 1 diabetes was
induced in 7-week-old male IGF-1R transgenic mice using strep-
tozotocin and followed for 8 weeks. Diastolic and systolic
function was assessed using Doppler and M-mode echocardiog-
raphy, respectively, in addition to cardiac catheterization. Car-
diac ﬁbrosis and cardiomyocyte width, heart weight index, gene
expression, Akt activity, and IGF-1R protein content were also
assessed.
RESULTS—Nontransgenic (Ntg) diabetic mice had reduced
initial (E)-to-second (A) blood ﬂow velocity ratio (E:A ratio) and
prolonged deceleration times on Doppler echocardiography com-
pared with nondiabetic counterparts, indicative markers of dia-
stolic dysfunction. Diabetes also increased cardiomyocyte width,
collagen deposition, and prohypertrophic and proﬁbrotic gene
expression compared with Ntg nondiabetic littermates. Overex-
pression of the IGF-1R transgene markedly reduced collagen
deposition, accompanied by a reduction in the incidence of
diastolic dysfunction. Akt phosphorylation was elevated 15-
fold in IGF-1R nondiabetic mice compared with Ntg, and this was
maintained in a setting of diabetes.
CONCLUSIONS—The current study suggests that cardiac over-
expression of IGF-1R prevented diabetes-induced cardiac ﬁbro-
sis and diastolic dysfunction. Targeting IGF-1R–Akt signaling
may represent a therapeutic target for the treatment of diabetic
cardiac disease. Diabetes 59:1512–1520, 2010
D
iabetes represents a major threat to human
health, with global incidence projected to reach
300 million by 2025 (1,2). Cardiovascular com-
plications including coronary heart disease and
peripheral vascular disease are regarded as primary
causes of morbidity and mortality in both type 1 and type
2 diabetes (3,4). In addition, clinical and experimental
evidence supports the existence of a distinct diabetic
cardiomyopathy, associated with adverse changes to the
structure and function of cardiomyocytes, which can
occur independent of macrovascular complications (5,6).
Left ventricular (LV) diastolic impairments (in LV ﬁlling,
relaxation, and/or diastolic distensibility) are evident early
in disease progression (7–9), often followed by later onset
of systolic dysfunction (e.g., reduced LV ejection fraction
and fractional shortening) (10). Functional alterations in
the diabetic heart occur concomitantly with development
of the structural abnormalities cardiomyocyte hypertro-
phy and cardiac ﬁbrosis (11–13). In both type 1 and 2
diabetes, this cardiomyopathy is a prognostic indicator,
particularly for mortality (14). New approaches to rescue
LV remodeling and dysfunction speciﬁcally in diabetic
myocardium are thus highly desirable.
Physiological heart growth or hypertrophy, which oc-
curs during normal postnatal development and can be
induced by exercise, is characterized by a normal cardiac
structure and gene expression (15). In contrast, patholog-
ical hypertrophy is characterized by ﬁbrosis, myoﬁber
disarray, reduced cardiac output, and eventual heart fail-
ure (15). IGF-1, structurally and functionally related to
insulin (16), plays a crucial role in stimulating physiolog-
ical LV hypertrophy and conferring protection against
cardiac dysfunction (17–19). The therapeutic potential of
IGF-1 has thus been extensively examined in an array of
cardiac pathologies, including heart failure and diabetes
(18,19). In dilated cardiomyopathy, eccentric hypertrophy,
and myocardial infarction (20–22), transgenic IGF-1 ex-
pression limited structural abnormalities such as myocyte
necrosis and ﬁbrosis (21). IGF-1 upregulation may also
improve systolic function, via restoration of normal Ca
2
handling and increased cardiomyocyte contractility (17,20).
Similar beneﬁts have been proposed in diabetic myocar-
dium (18,23), although in vivo cardiac functional studies
have been limited. Furthermore, chronic IGF-1 may repre-
sent a ﬂawed therapeutic approach for diabetes-induced
LV dysfunction and remodeling, as both transgenic and
pharmacological IGF-1 approaches signiﬁcantly elevate
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undesirable effects on nonmyocytes and other tissues. For
instance, IGF-1 may induce ﬁbroblast proliferation (24)
and increase size of other organs including brain and
kidney (17,25,26).
The current study seeks to circumvent the problem of
potential noncardiac IGF-1 effects by using a cardiomyo-
cyte-speciﬁc IGF-1R transgenic (Tg) mouse (27), which
develops physiological cardiac hypertrophy and enhanced
systolic function, without histopathology (27). Despite
compelling evidence for IGF-1 preservation of cardiac
function, the role of cardiac IGF-1R speciﬁcally in protect-
ing LV function and structure in the context of diabetes-
induced cardiomyopathy in vivo has not been examined.
Thus, the present study tested the hypothesis that car-
diomyocyte-speciﬁc IGF-1R protects against diabetes-in-
duced LV diastolic dysfunction and remodeling, using a
streptozotocin (STZ)–induced mouse model of diabetes in
vivo.
RESEARCH DESIGN AND METHODS
Animal model. This study was conducted in accordance to National Health
and Medical Research Council of Australia guidelines, and approved by the
Alfred Medical Research and Education Precinct Animal Ethics Committee.
Heterozygote 7-week-old IGF-1R Tg mice and their age-matched nontrans-
genic (Ntg) male littermates (FVB/N background) were used. These mice were
generated by cloning a cDNA insert for the human IGF-1R gene into a
Sa1I-digested -myosin heavy chain promoter construct (originated from the
laboratory of Dr. Seigo Izumo, Beth Israel Deaconess Medical Center and
Harvard Medical School). The bacterial sequence was removed from the
construct and injected into the male pronucleus of fertilized single-cell FVB/N
embryos on an FVB/N background. This transgenic line (no. 7) exhibited a
20-fold increase in IGF-1R expression speciﬁcally in the myocardium, without
changes in IGF-1 plasma or tissue levels, as previously described (27).
Diabetes was induced by ﬁve consecutive daily intraperitoneal STZ injections
(55 mg/kg, in 0.1 mol/l citrate buffer, pH 4.5; Sigma Aldrich, St. Louis MO);
sham mice were administered an equivalent volume of citrate buffer (28).
Saphenous vein blood glucose levels were measured every 2 weeks using a
hand-held glucometer (Accu-check Advantage; Roche, Basel, Switzerland),
with blood glucose levels exceeding 28 mmol/l considered diabetic. Diabetes
then progressed for 8 weeks (13), i.e., to 15 weeks of age, and submandibular
blood was collected from conscious mice for ﬁnal plasma glucose assessment
(Austin Pathology Service, Melbourne, Victoria, Australia).
Analysis of LV function. Animals were placed under light anesthesia with a
cocktail of ketamine, xylazine, and atropine (100 mg/kg, 10 mg/kg, and 1.2
mg/kg, respectively, i.p.) for echocardiography. Baseline echocardiography
(M-mode two-dimensional echocardiography) was performed at 6 weeks of
age, using a Philips iE33 echocardiography system with a 15-MHz linear array
transducer (29), prior to induction of diabetes (at 7 weeks). End point
echocardiography (both two-dimensional M-mode and three-dimensional
Doppler echocardiography) was performed at 15 weeks of age. Derived
echocardiography parameters included interventricular septum, LV posterior
wall thickness, LV diastolic dimension (LVDd), LV systolic dimension (LVDs),
and fractional shortening (calculated as [(LVDd  LVDs)/LVDd]  100%). LV
ﬁlling was assessed on transmitral Doppler echocardiography, on the ratio of
initial (E) and second (A) blood ﬂow velocities (E:A ratio) and E velocity
deceleration time (30). Cardiac catheterization was also performed after 8
weeks of diabetes in anesthetized mice (ketamine 100 mg/kg, xylazine 10
mg/kg, atropine 1.2 mg/kg i.p.), by placing a micromanometer-tipped catheter
(1.4F; Millar Instrument Co, Houston, TX) in the LV or aorta (29). Parameters
measured included aortic systolic and diastolic blood pressure, LV  dP/dt
(pressure change during contraction/relaxation), LV systolic pressure, and LV
end-diastolic pressure (LVEDP).
Tissue collection and histology. After cardiac catheterization, atria, ventri-
cles, and lungs were rinsed in saline and lightly blotted and wet weight was
determined. Whole blood was collected for analysis of glycated hemoglobin
(GHb) (Austin Pathology Service), plasma insulin (n  5–8/group, insulin
ELISA kit; Millipore, Billerica, MA), and free fatty acids (n  3/group, Nefa-C
assay kit; Wako Chemicals, Richmond, VA, as per manufacturer’s instruc-
tions). Tibias were collected and digested with 1 M NaOH (overnight, 37°C),
and their lengths were measured using vernier calipers. Hearts were cut at the
horizontal short-axis plane, and the middle portion of the ventricle was
snap-frozen in liquid nitrogen and stored at 80°C for biochemical analysis.
The basal portion of the ventricle was ﬁxed in 10% neutral buffered formalin
(Australian Biostain, Melbourne, Australia), and parafﬁn-embedded for histo-
logical analysis of 4-m cross-sections. Hematoxylin-eosin (H-E)–stained
sections were photographed under light microscopy at 400 magniﬁcation
(with resolution of 2,048  1,536 pixels and 300  300 dpi), and cardiomyo-
cyte width was manually determined as the shortest dimension per cardio-
myocyte (m), using Olympus Image Pro-plus (Media Cybergenetics,
Bethesda, MD), with a photographed scale of the 400 objective lens for
calibration. Mean values ( SEM) for each experimental group were calcu-
lated from the mean of 100 individual cardiomyocytes (from 6–8 ﬁelds) per
mouse. Cardiac collagen deposition was also assessed, on 0.1% picrosirius
red–stained sections. Ten ﬁelds were randomly chosen, taking care to avoid
arterial collagen deposition, and photographed via light microscopy at 200
magniﬁcation. Collagen stained an intense red color, which was measured and
analyzed using Olympus Image Pro-plus as a ratio of area of collagen to total
area of image.
RNA and protein extraction. RNA and protein were extracted from frozen
ventricle as previously described (31).
Analysis of gene expression. Changes in cardiac 	-myosin heavy chain (a
marker of hypertrophy) and pro–collagen III (a marker of ﬁbrosis) expression
used real-time PCR. DNase-treated RNA was reverse-transcribed (Taqman
Reverse Transcription reagents; Applied Biosystems) using the Gene-Amp
PCR system 9700 (Applied Biosystems) to produce cDNA template concen-
trations of 20 ng/l (13). 	-myosin heavy chain expression was quantitated
using SYBR Green chemistry; pro–collagen III used TaqMan universal mas-
termix (Applied Biosystems), using the ABI Prism 7700 Sequence Detection
System, with ribosomal 18S as a control. All primers and probes were
produced from murine-speciﬁc sequences published on GenBank at previ-
ously determined optimal concentrations (31). The comparative delta-delta
cycle threshold method was used to analyze changes in gene expression as a
relative fold change of Ntg sham mice, as previously described (31). Northern
blot analysis was performed to analyze gene expression of the hypertrophic
markers atrial (ANP) and B-type (BNP) natriuretic peptide, as previously
described (27). Total RNA (7.5 g) was denatured and loaded onto an agarose
gel, and transferred to a Hybond–N membrane (Amersham Biosciences,
Stockholm, Sweden).
Analysis of protein expression. SDS-PAGE and Western blotting were
performed to determine protein expression of phospho:total-Akt and IGF-1R:
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Phospho- and total Akt
antibodies were obtained from Cell Signaling Technologies (catalog nos.
9271S and 9272; 1:1,000 dilution) and used according to manufacturer’s
instructions, with bands detected at 60 kDa. IGF-1R and GAPDH antibodies
were obtained from Santa Cruz Biotechnology (catalog nos. sc713 and
sc32233; 1:1,000 dilution) and used according to manufacturer’s instructions,
with bands detected at 97 and 37 kDa, respectively.
Statistical analysis. Results are presented as mean  SE. Two-way ANOVAs
were run on all raw data using SigmaStat (Version 3.5; Erkath, Germany) and
used to identify differences between genotype (Ntg or IGF-1R) and disease
(diabetic or sham) groups, followed by Student Newman-Keuls post hoc test,
unless otherwise stated. P  0.05 was considered signiﬁcant. Unpaired t tests
were also used to detect signiﬁcance between Ntg sham and Ntg diabetic
animals, where appropriate.
RESULTS
Induction of diabetes. STZ-induced diabetic Ntg and
IGF-1R Tg mice exhibited marked hyperglycemia, on both
plasma glucose and GHb in comparison with age-matched
nondiabetic shams (Table 1), without genotype-dependent
differences. Plasma insulin decreased in both Ntg and
IGF-1R Tg STZ mice (P 
 0.001 on two-way ANOVA, n 
5–8, Table 1). Furthermore, plasma free fatty acids in-
creased from basal (0.4 mmol/l in Ntg sham mice, n  2)
to 1.99  0.14 and 1.57  0.15 mmol/l in Ntg STZ and
IGF-1R Tg STZ mice (P 
 0.001 on two-way ANOVA, both
n  3), respectively. Body weight and tibia length were
comparable across the four groups at the end of the study.
IGF-1R Tg mice exhibited greater heart mass than Ntg
mice, by 30% whether normalized to body weight or tibia
length (Table 1), as previously observed in this strain (27).
Diabetes however did not signiﬁcantly change net heart
weight–to–body weight or heart weight–to–tibia length
ratio, in either Ntg or Tg mice.
K. HUYNH AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, JUNE 2010 1513IGF-1R prevents diabetes-induced cardiomyocyte hy-
pertrophy. Cardiomyocyte width was signiﬁcantly greater
in Ntg diabetic mice versus Ntg sham (Fig. 1A and B),
despite no net increase in heart weight–to–body weight or
heart weight–to–tibia length ratios. IGF-1R Tg develop
physiological cardiac hypertrophy with a 46% increase in
myocyte volume (27). Consistent with the initial charac-
terization of IGF-1R Tg mice, IGF-1R sham mice had
enlarged cardiomyocytes versus Ntg sham. In contrast to
the diabetes-induced increase in myocyte width in Ntg,
diabetes failed to elicit any further increase in cardiomy-
ocyte width in IGF-1R Tg mice (Fig. 1A and B). As with
cardiomyocyte width, gene expression of 	-myosin heavy
chain, ANP, and BNP (Fig. 2A and B) were greater in Ntg
diabetic mice versus Ntg sham. Expression of all three
hypertrophic markers was also increased in IGF-1R sham
versus Ntg sham, but again diabetes failed to induce
further expression of these hypertrophic markers in the
IGF-1R Tg animals.
IGF-1R limits diabetes-induced cardiac ﬁbrosis. On
sirius red–stained sections, diabetes signiﬁcantly in-
creased cardiac collagen deposition by 2.2  0.3-fold in
Ntg mice (P 
 0.05; Fig. 3A and B). Cardiac collagen
content in IGF-1R sham mice was similar to Ntg sham
mice. Expression of the IGF-1R transgene signiﬁcantly
reduced the extent of cardiac ﬁbrosis in diabetic mice. In
contrast to Ntg animals, diabetes failed to increase colla-
gen content in IGF-1R Tg hearts, where collagen deposi-
tion of IGF-1R diabetic mice was 1.2  0.1-fold IGF-1R
sham (P  not signiﬁcant). Gene expression of the ﬁbrotic
marker pro–collagen III tended to increase in Ntg diabetic
mice (2.4  0.6-fold Ntg sham, P  0.06; unpaired t test).
Diabetes failed to upregulate pro–collagen III expression
in IGF-1R Tg mice (pro–collagen III expression in IGF-1R
diabetic mice was 0.87  0.3-fold that of IGF-1R sham
mice, P  not signiﬁcant).
IGF-1R protects against diastolic dysfunction. Consis-
tent with IGF-1R mice developing physiological cardiac
hypertrophy, IGF-1R Tg mice had increased LV wall thick-
nesses and enhanced systolic function (estimated by
fractional shortening) versus Ntg at baseline by echocar-
diography (6–7 weeks of age, prior to induction of diabe-
tes; Table 2). After 8 weeks of diabetes, systolic
dysfunction was not evident; fractional shortening, LV
posterior wall thickness, and LV systolic dimension were
comparable in Ntg sham and Ntg diabetic mice (Table 2).
The enhanced systolic function seen in IGF-1R Tg mice at
baseline was maintained at 15 weeks of age, in both sham
TABLE 1
Postmortem systemic analysis of Ntg and IGF-1R sham and diabetic mice (15 weeks of age)
Ntg sham Ntg diabetic IGF-1R sham IGF-1R diabetic
n  9 n  9 n  12 n  9
Blood glucose (mM) 8.5  0.8 35.5  1.1* 10.5  1.0 35.4  1.7*
GHb (%) 2.4  0.2 9.0  0.6* 2.3  0.1 8.7  0.5*
Plasma insulin (ng/ml) 1.3  0.2 0.4  0.0* 1.1  0.2 0.6  0.1*
BW (g) 30.1  1.4 28.7  0.6 30.7  0.9 29.4  0.8
HW (mg) 122.4  6.3 116.2  3.2 165.5  3.3†‡ 154.8  5.2†‡
LW (mg) 154.7  4.2 154.8  4.9 151.0  3.5 148.8  7.4
TL (mm) 16.3  0.2 16.5  0.1 16.5  0.6 16.5  0.2
HW/BW (mg/g) 4.06  0.08 4.05  0.05 5.46  0.10†‡ 5.27  0.09†‡
LW/BW (mg/g) 5.31  0.25 5.11  0.24 5.27  0.15 5.01  0.32
HW/TL (mg/mm) 7.48  0.32 7.04  0.18 9.97  0.13†‡ 9.38  0.24†‡
LW/TL (mg/mm) 9.41  0.32 9.39  0.32 9.15  0.23 9.13  0.47
BW, body weight; HW, heart weight; LW, lung weight; TL, tibial length. *P 
 0.05 vs. sham of the same genotype; †P 
 0.05 vs. Ntg sham;
‡P 
 0.05 vs. Ntg diabetic.
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FIG. 1. Cardiomyocyte width is increased by diabetes and IGF-1R overexpression on histological analysis of ventricular cross-sections stained
with H-E. A: Representative sections from the LV of sham and diabetic Ntg and IGF-1R mice (H-E stain; magniﬁcation 400). Scale bars show 20
m. B: Cardiomyocyte width pooled data. n  8–12 in each group; *P < 0.001 vs. Ntg sham; †P < 0.001 vs. Ntg diabetes. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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diastolic dysfunction was evident compared with Ntg
sham mice (decreased E wave velocity and E:A ratio,
increased A wave velocity and a trend for decreased E
wave velocity, on Doppler ﬂow echocardiography, Fig.
4A–E). Diastolic function was similar in IGF-1R sham and
Ntg sham. A fall in the E:A ratio was also observed in
IGF-1R diabetic mice compared with IGF-1R sham mice.
Diabetes reduced the E:A ratio by 44  5% in Ntg mice, and
by 35  7% in IGF-1R Tg mice. However, the number of
mice with normal diastolic function (arbitrarily deﬁned as
E:A  1.5; Fig. 4C) appeared greater in IGF-1R diabetic
mice compared with Ntg diabetic mice. Diabetes-induced
prolongation in deceleration time was signiﬁcantly ame-
liorated by IGF-1R upregulation (Fig. 4F). LV catheteriza-
tion performed after 8 weeks of diabetes further conﬁrmed
the presence of diastolic dysfunction in Ntg diabetic mice
compared with sham mice (LV-dP/dt decreased by 20 
5%; P 
 0.05, unpaired t test; Table 3). Diabetes also
tended to increase LVEDP in Ntg diabetic mice (again by
20%, P  0.06 on two-way ANOVA; Fig. 4G). In IGF-1R
mice however, diabetes failed to signiﬁcantly impact on
either LV-dP/dt or LVEDP. Together, these data suggest
that transgenic IGF-1R expression exhibited some protec-
tion against diabetes-induced diastolic dysfunction.
Preserved Akt activity in diabetic IGF-1R transgenic
mice. It has previously been shown that the physiological
hypertrophy observed in IGF-1R is associated with
activation of the phospho-inositide 3-kinase (PI3K)
(p110)–Akt pathway (27) and Akt is a critical mediator
of physiological heart growth (32). In the current study,
Akt phosphorylation was elevated in ventricles of
IGF-1R sham mice by more than 15-fold versus Ntg
sham, from 0.27  0.04 to 4.26  0.54 arbitrary units
(AU) in Ntg and IGF-1R sham mice, respectively (Fig.
5A), which was maintained in diabetes. Akt phosphory-
lation was 3.92  0.82 AU in IGF-1R Tg STZ mice
(P(genotype) 
 0.001 on two-way ANOVA). Interest-
ingly, a modest increase in phospho-Akt (approximately
fourfold) was also observed in Ntg diabetic mice com-
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FIG. 2. A: Gene expression of -myosin heavy chain (hypertrophic marker) was analyzed on real-time PCR and normalized against 18S expression.
n  8–11 for each group. B: Representative Northern blot showing total RNA. GAPDH was used to normalize for RNA loading (insert). Gene
expression of ANP (n  9–10 per group) and BNP (n  4–5 per group) was assessed. Mean values for Ntg sham were normalized to 1. *P < 0.05
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FIG. 3. A: Representative sections from the LV of sham and diabetic Ntg and IGF-1R mice. Collagen deposition appears red (sirius red stain;
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lular signal–related kinase 1/2 phosphorylation however
were detected in the groups of mice (results not shown).
Lastly, as shown in Fig. 5B, the level of IGF-1R protein
was comparable between IGF-1R sham and IGF-1R
diabetic mice.
DISCUSSION
Diabetic cardiomyopathy is typically associated with dia-
stolic dysfunction, myocardial ﬁbrosis, and cardiomyocyte
hypertrophy. The primary aim of the present study was to
elucidate whether cardiac-speciﬁc upregulation of IGF-1R
prevented cardiac dysfunction and adverse structural re-
modeling associated with pathophysiology of the diabetic
heart. Key ﬁndings from the study provide evidence that
IGF-1R speciﬁcally protects against diabetes-induced dia-
stolic dysfunction and cardiac ﬁbrosis. IGF-1R induced
activation of the cell survival kinase Akt was maintained in
a setting of diabetes, suggesting that beneﬁcial actions of
IGF-1R may be linked to promotion of physiological
hypertrophy. The attenuation of diabetes-induced struc-
tural and functional cardiac damage mediated by IGF-1R
signaling was independent of the degree of hyperglycemia
and body weight.
IGF-1R promotes physiological hypertrophy and is
protective in a setting of diabetes. Physiological car-
diac growth occurs during postnatal development, and in
response to long-term exercise training (15). This form of
hypertrophy is associated with normal or enhanced car-
diac function and normal cardiac structure. In contrast,
pathological cardiac hypertrophy may arise as a compen-
satory mechanism against increased myocyte stress in
many disease states. Any initial beneﬁt is however over-
ridden by eventual derangement of myocardial architecture
and deterioration of function (15). Diabetic cardiomyopa-
thy is characterized by adverse structural changes to the
heart, including increased cardiac ﬁbrosis (pathological in
nature) and cardiomyocyte hypertrophy. Our results show
that diabetes increased several markers of cardiomyocyte
hypertrophy, including cardiomyocyte width as well as
gene expression of 	-myosin heavy chain, ANP, and BNP
as previously described (13). No changes in heart weight–
to–body weight or heart weight–to–tibia length ratios
were observed in Ntg diabetic mice, indicating no net
increased heart size. Diabetes-induced cardiomyocyte hy-
pertrophy in the absence of gross LV mass increase may
result from loss of cardiomyocytes via hyperglycemia-
induced apoptosis and necrosis (23,33). Compensatory
hypertrophy of the remaining viable cardiomyocytes, in
addition to ﬁbrosis, may then occur, and therefore any
increase in overall size of each cardiomyocyte is counter-
balanced by a reduction in the total number of myocytes
(33). The upregulation of hypertrophic gene expression
observed in this study is consistent with this. The causes
underlying the diabetes-induced hypertrophic response is
multifaceted, and may involve metabolic derangements
such as impaired glucose handling (34) and oxidative
stress (23,31).
Adaptive physiological hypertrophy in both humans (35)
and animal models (27,36) has been associated with
increased IGF-1 formation and/or activation. This hyper-
trophy is characterized by normal heart structure and
absence of myocardial ﬁbrosis (17,27). In contrast, patho-
logical hypertrophy (15) is accompanied by cardiac ﬁbro-
sis and detrimental changes in LV function (such as that
observed in diabetes in the present study). Consistent with
previous ﬁndings (27), we demonstrated signiﬁcant en-
largement in cardiomyocyte size in IGF-1R Tg mice, ac-
companied by increased heart weight–to–body weight and
heart weight–to–tibia length ratios, increased LV wall
thicknesses, and enhanced systolic function compared
with Ntg mice. Surprisingly, markers commonly associ-
ated with pathological hypertrophy (	-myosin heavy
chain, ANP, and BNP) were also increased in IGF-1R Tg
compared with Ntg sham mice. However, this is consistent
with both the original characterization and the recent
contention as to whether fetal gene expression alone is an
indicator of whether hypertrophy is “pathological” or
“physiological” in nature (27,29). Histological analysis of
cardiac structure and analysis of LV function might thus be
more appropriate markers of the type of hypertrophy
present. Importantly, diabetes failed to elicit further in-
creases in any parameter of hypertrophy studied in IGF-1R
mice, suggesting that the IGF-1R–induced physiological
hypertrophic response was able to blunt the pathological
hypertrophic response induced by diabetes. Expression of
the IGF-1R transgene was previously shown to blunt
pressure-overload induced pathological growth (27). To-
gether, this demonstrates that transgenic IGF-1R expres-
sion is associated with the preservation of normal cardiac
structure and function in the setting of diabetes.
IGF-1R overexpression inhibits diabetes-induced
cardiac ﬁbrosis. Increased cardiac ﬁbrosis is a common
hallmark of the diabetic heart (11,37). The resultant in-
creased LV stiffness further compromises the diabetic
heart’s ability to contract and relax efﬁciently (14). In the
present study, Ntg diabetic mice exhibited increased car-
diac collagen deposition, consistent with previous ﬁndings
in rats (38) and there was a tendency for elevated pro–
collagen III gene expression compared with Ntg sham
TABLE 2
Echocardiographic analysis of heart dimensions and function
Baseline (pre-diabetic,
7 weeks old) End point measurements (15 weeks old)
Ntg IGF-1R
Ntg
sham
Ntg
diabetic
IGF-1R
sham
IGF-1R
diabetic
n  18 n  21 n  9 n  9 n  12 n  9
Heart rate (bpm) 436  14 423  12 391  20 414  12 370  13 402  8
LV posterior wall thickness (mm) 0.75  0.03 0.89  0.03* 0.71  0.02 0.76  0.03 0.96  0.03† 0.90  0.03†
LV end diastolic dimension (mm) 3.32  0.06 3.27  0.04 3.70  0.07 3.52  0.08 3.26  0.10† 3.58  0.10‡
LV end systolic dimension (mm) 2.02  0.08 1.65  0.07* 2.40  0.07 2.19  0.12 1.66  0.14† 1.95  0.07
Fractional shortening (%) 40  25 0  2* 35  23 7  25 0  3† 45  1†
*P 
 0.05 vs. Ntg sham (baseline measurement); †P 
 0.05 vs. Ntg sham and Ntg diabetic; ‡P 
 0.05 vs. IGF-1R sham.
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with increased cardiac ﬁbrosis on either marker (in line
with its “physiological” phenotype), as collagen deposition
in IGF-1R sham mice was similar to Ntg sham mice.
Furthermore, in contrast to Ntg mice, no difference in
collagen deposition was detectable between IGF-1R sham
and IGF-1R diabetic mice. This suggests that IGF-1R
overexpression confers protection against cardiac ﬁbrosis
induced by diabetes. Procollagen gene expression of the
IGF-1R diabetic mice also tended to decrease compared
with Ntg diabetic mice; however this change was not
signiﬁcant. The lack of cardiac ﬁbrosis in diabetic IGF-1R
Tg mice lends further support to the existing body of
evidence that IGF-1R–induced hypertrophy is of a physio-
logical nature, providing protection against adverse car-
diac remodeling (27).
IGF-1R expression attenuates diastolic dysfunction.
In the present study, diastolic and systolic function was
measured both noninvasively (echocardiography) and in-
vasively (LV catheterization). LV diastolic dysfunction is
considered one of the earliest hallmarks of diabetic car-
diomyopathy, occurring prior to the onset of systolic
dysfunction (8,39). Doppler echocardiography revealed
that Ntg diabetic mice exhibited a pronounced decrease in
the transmitral E:A ratio, 60% of the mice had an E:A
ratio 
1.5, and deceleration time was prolonged, all indic-
ative of diastolic dysfunction. This was further supported
by LV catheterization, on which diabetes reduced LV-dP/
dt, with a trend for increased LVEDP. Taken together,
these results support the presence of diabetes-induced
diastolic dysfunction, as previously described (8,30,39).
Our observation is consistent with increased collagen
deposition observed in Ntg diabetic mice; the onset of LV
diastolic dysfunction may be secondary to changes in the
extracellular matrix scaffold of the heart, resulting in
increased cardiac stiffness (37). Although transgenic
IGF-1R expression itself did not enhance diastolic function
in the absence of diabetes, it prevented the diabetes-induced
prolongation of LV deceleration time and increased the
number of diabetic mice with normal diastolic function.
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FIG. 4. Impact of cardiac-speciﬁc IGF-1R overexpression on diabetes-induced diastolic dysfunction. A: Representative mitral ﬂow patterns from
pulsed wave Doppler echocardiography. Diabetes (B) tends to decrease E velocity and (C) increases peak A velocity, with (D) net reduction in
E:A wave ratio in both Ntg and IGF-1R diabetic mice. IGF-1R (E) reduces incidence of diastolic dysfunction, (F) restores normal deceleration
time, and (G) tends to improve LV end diastolic pressure. n  7–12 in each group; *P < 0.05 vs. sham of the same genotype; †P < 0.05 vs. Ntg
counterpart.
K. HUYNH AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, JUNE 2010 1517Diabetes also failed to elevate LVEDP in IGF-1R Tg mice. To
our knowledge, we provide the ﬁrst evidence that IGF-1R
signaling speciﬁcally ameliorates diabetes-induced diastolic
dysfunction and ﬁbrosis in a mouse model in vivo.
We chose our 8-week study period of STZ-induced
diabetes in mice to speciﬁcally assess the impact of
IGF1-R on diastolic function in isolation. As such, no
difference was detected in systolic function (assessed by
both fractional shortening and LVdP/dt) of Ntg diabetic
mice compared with Ntg sham mice. The duration of
diabetes is important, as systolic dysfunction in humans
often manifests with a later onset than diastolic dysfunc-
tion (8,39). Our observations of diastolic dysfunction
accompanied by a lack of systolic dysfunction in the
diabetic heart are consistent with previous reports (40,41).
However, species and strain clearly are important in
dictating the presence of systolic dysfunction. Eight weeks
of hyperglycemia is sufﬁcient to induce systolic dysfunc-
tion in Wistar rats (9) and C57/BL6J mice (42). In contrast,
8 weeks of STZ-induced diabetes was not associated with
impaired systolic function in our mice, which were gener-
ated on an FVB background. Importantly, FVB and C57
backgrounds show comparable cardiac (diastolic dysfunc-
tion, cardiomyocyte hypertrophy, and ﬁbrosis) and blood
glucose sensitivities to the STZ mouse model of diabetes
(43,44). Consistent with previous reports (27), mice over-
expressing IGF-1R exhibited enhanced systolic function
(on echocardiography-derived fractional shortening) com-
pared with Ntg mice, both prior to and after induction of
diabetes (6 and 15 weeks of age, respectively). Because
systolic function was preserved in our model of diabetes,
IGF-1R Tg mice had increased systolic function compared
with Ntg mice that was not impacted by the presence of
diabetes.
Cardioprotective signaling in the diabetic heart. PI3K
(p110) and Akt are important downstream effectors of
IGF-1R signaling, critical for regulation of cardiac growth
and survival (27,32,45,46). We observed a marked in-
crease in ventricular phospho-Akt in IGF-1R Tg mice in
the current study, in both the absence and presence of
diabetes. Contrary to a previous report (47), Akt phos-
phorylation was increased in Ntg diabetic animals. This
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FIG. 5. A: Representative Western blot showing phosphorylation of Akt and total Akt in sham (Sh) and diabetic (D) mice (insert), and
quantitative analysis of Akt phosphorylation normalized to total Akt (left panel). Mean values for Ntg sham were normalized to 1. n  4–6 in each
group; *P < 0.05 vs. Ntg sham; †P < 0.05 vs. Ntg counterpart. B: Representative Western blot showing protein levels of IGF-1R and GAPDH protein
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TABLE 3
Analysis of cardiac function via cardiac catheterization
Ntg
sham
Ntg
diabetic
IGF-1R
sham
IGF-1R
diabetic
n  8 n  7 n  9 n  9
Heart rate (bpm) 349  10 364  15 369  17 372  11
Ao SBP (mmHg) 107.8  3.7 87.0  3.3* 99.4  2.8 88.5  2.8*
Ao DBP (mmHg) 73.9  3.6 59.2  3.1* 68.2  2.5 60.5  3.5
LVdP/dt (mmHg/s) 7,237  293 8,297  586 8,628  426† 8,029  557
LVdP/dt (mmHg/s) 6,699  361 5,543  314† 6,006  284 5,500  341
LVSP (mmHg) 102.8  2.5 90.2  2.2* 96.9  2.6 92.7  3.1
Ao SBP, aortic systolic blood pressure; Ao DBP, aortic diastolic blood pressure; LVSP, left ventricular systolic pressure. *P 
 0.05 vs. sham
of the same genotype; †P 
 0.05 vs. Ntg sham (on unpaired t test).
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tory response to the functional and structural derange-
ments in the diabetic heart, thus warranting further
investigation. The IGF-1R–PI3K(p110)–Akt pathway plays
a crucial role in inducing physiological (but not patholog-
ical) hypertrophy (19,27,46). Maintained elevated Akt ac-
tivity in hearts of IGF-1R, together with improvements in
both diastolic function and cardiac structure compared
with Ntg diabetic mice, suggest the protective effects of
IGF-1R signaling in diabetes may be attributable to IGF-1R
induction of physiological hypertrophy. These ﬁndings
may provide an additional mechanism by which regular
exercise (which also activates this cardioprotective cas-
cade [15]) improves morbidity and mortality in patients
with diabetes (48–50).
A previous study reported that IGF-1 ligand transgenic
expression in an STZ mouse model of diabetes protected
the heart against diabetes-induced diastolic dysfunction
(23). However, collagen deposition was not examined, and
mice were studied only for up to 30 days after STZ
treatment. The authors acknowledged that limitations of
their study included higher circulating IGF-1 levels, which
may have contributed to their results, in addition to the
relatively short period of diabetes. Kajstura et al. attribute
some of the IGF-1–mediated protection to inhibition of
apoptosis, necrosis, and angiotensin II–mediated oxidative
stress (23). Here, we demonstrate that IGF-1R overexpres-
sion is beneﬁcial even in the absence of elevated circulat-
ing IGF-1 levels, and over a longer period of time (8 weeks
vs. 30 days). Furthermore, we provide another potential
mechanism to explain the protective properties of the
IGF-1R, i.e., activation of Akt.
To our knowledge, this study is the ﬁrst to assess the
cardioprotective effect of IGF-1R overexpression on dia-
betes-induced cardiac dysfunction and remodeling. We
have demonstrated that overexpression of IGF-1R specif-
ically in the heart attenuated diabetes-induced cardiac
ﬁbrosis, and prevented diastolic dysfunction. This cardio-
protective effect may be mediated via maintenance of
enhanced IGF-1–PI3K(p110)–Akt signaling, although fur-
ther investigation is required. Given that cardiac compli-
cations are a major contributor to morbidity and mortality
in both type 1 and type 2 diabetic patients, studies such as
this may identify possible new therapeutic approaches
toward reducing cardiac structural and functional damage
induced by diabetes.
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